PBS restrictions on infliximab in Crohn’s disease have been eased for biosimilar brands to allow Streamlined or Telephone Authority for ongoing prescriptions. The easing of the restrictions, intended by the government to drive uptake of biosimilars such as Renflexis and Inflectra, will mean clinicians no longer have apply in writing by post and wait for ...
Written authority no longer needed for infliximab biosimilars
By Michael Woodhead
4 Jul 2018